Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: Results from two replicate 48-week studies

International Journal of COPD

Volumn 9, Issue , 2014, Pages 629-645

  Ferguson, Gary T ^a   Feldman, Gregory J ^b   Hofbauer, Peter ^c   Hamilto, Alan ^d   Allen, Lisa ^e   Korducki, Lawrence ^e   Sachs, Paul ^f  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b S Carolina Pharmaceutical Research   (United States)

^c Pneumologie   (Germany)

^d BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Pulmonary Associates of Stamford   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Olodaterol

Indexed keywords

CREATINE KINASE; OLODATEROL; PLACEBO; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; INCIDENCE; INHALER; LONG TERM CARE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT RISK; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ASIA; AUSTRALIA; CLINICAL TRIAL; DRUG EFFECTS; EQUIPMENT DESIGN; GERMANY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; NEBULIZER; NEW ZEALAND; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AREA UNDER CURVE; ASIA; AUSTRALIA; BENZOXAZINES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NEW ZEALAND; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84902997339     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S61717     Document Type: Article

References (30)

1. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed July 15, 2013.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543-1554.
4. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):778-784.
5. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1994;7(2):103-107.
6. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155(3):291-299.
7. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-441.
8. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53-62.
9. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600-609.
10. Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20(4):1410-1414.
11. 2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124(6):1217-1221.
12. 2-agonist, in patients with asthma. Am J Respir Crit Care Med. 2012;185:A3963 (Abstract).
13. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666-672.
14. 1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPD. Am J Respir Crit Care Med. 2012;185:A2930 (Abstract).
15. van Noord JA, Korducki L, Hamilton A, Koker P. Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients. Am J Respir Crit Care Med. 2009;179:A6183 (Abstract).
16. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071575.pdf. Accessed April 26, 2012.
17. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215-1219.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
19. European Medicines Agency. Statistical principles for clinical trials. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Accessed July 24, 2013.
20. McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis. Eur Respir J. 2013;42 Suppl 57:749s, P3633 (Abstract).
21. Tomlinson B, Cruickshank JM, Hayes Y, et al. Selective β-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. Br J Clin Pharmacol. 1990;30(5):665-672.
22. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-708.
23. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies. Eur Respir J. 2013;42 Suppl 57:145s, P763 (Abstract).
24. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: two 48-week studies. Eur Respir J. 2013;42 Suppl 57:146s, P764 (Abstract).
25. Ferguson GT, Sachs P, Hamilton A, Tetzlaff K, Korducki L, Koch A. Efficacy of olodaterol once daily (QD) via Respimat® in GOLD 2/3 COPD patients not receiving background therapy: pooled data from 48-week studies. Abstract 727A presented at CHEST, Chicago, IL, USA, October 26-31, 2013.
26. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf. Accessed August 7, 2013.
27. Derom E, Westerman J, Grönke L, et al. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease (VIVACITO). Abstract D44 presented at American Thoracic Society; San Diego, CA, USA. May 16-21, 2014.
28. 1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies. Eur Respir J. 2013;42 Suppl 57:982s, 4635 (Abstract).
29. 1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies. Abstract 749A presented at CHEST, Chicago, IL, USA, October 26-31, 2013.
30. Maltais F, Kirsten A, Hamilton A, De Sousa D, Wang F, Decramer M. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies. Abstract 748A presented at CHEST, Chicago, IL, USA, October 26-31, 2013.